FDA's Tykerb decision could endorse new GSK R&D process

03/10/2007 | Wall Street Journal, The

If the FDA clears the cancer drug Tykerb this week, it could be seen as support for a new research-and-development technique used by GlaxoSmithKline. The breast-cancer drug was sent to the FDA for review under a new company policy granting scientists in seven specific disease areas more autonomy over research conducted in their areas.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC